Cefepime Dosing for UTI
For uncomplicated or complicated urinary tract infections in adults with normal renal function, administer cefepime 0.5-1 g IV every 12 hours for mild to moderate infections, or 2 g IV every 12 hours for severe infections, with treatment duration of 7-10 days. 1
Standard Dosing by Severity
Mild to Moderate UTI (including pyelonephritis)
- Dose: 0.5-1 g IV every 12 hours
- Duration: 7-10 days
- Pathogens covered: E. coli, K. pneumoniae, P. mirabilis 1
Severe UTI (including pyelonephritis)
- Dose: 2 g IV every 12 hours
- Duration: 10 days
- Pathogens covered: E. coli, K. pneumoniae 1
The European Association of Urology 2024 guidelines support cefepime at 1-2 g twice daily for uncomplicated pyelonephritis requiring hospitalization, noting that lower doses have been studied but higher doses are recommended 2.
Renal Dose Adjustments
Critical: Cefepime requires dose reduction based on creatinine clearance (CrCl) to prevent neurotoxicity 1.
CrCl 30-60 mL/min
- 0.5 g dose → 500 mg every 24 hours
- 1 g dose → 1 g every 24 hours
- 2 g dose → 2 g every 24 hours
CrCl 11-29 mL/min
- 0.5 g dose → 500 mg every 24 hours
- 1 g dose → 500 mg every 24 hours
- 2 g dose → 1 g every 24 hours
CrCl <11 mL/min
- 0.5 g dose → 250 mg every 24 hours
- 1 g dose → 250 mg every 24 hours
- 2 g dose → 500 mg every 24 hours
Hemodialysis
- Initial: 1 g on day 1
- Maintenance: 500 mg every 24 hours (given after dialysis on dialysis days) 1
Pediatric Dosing (2 months to 16 years)
Dose: 50 mg/kg IV every 12 hours for uncomplicated and complicated UTIs (including pyelonephritis)
- Maximum dose: Do not exceed adult dosing
- Duration: Same as adults (7-10 days) 1
Administration
- Route: Intravenous only for UTI indications
- Infusion time: Administer over approximately 30 minutes 1
- Timing: Maintain consistent daily administration times, especially in renal impairment
Clinical Considerations
Efficacy data: Real-world studies demonstrate 93.2% clinical efficacy and 85.4% bacteriological efficacy with cefepime for severe UTIs at doses of 1-2 g daily for 7-14 days 3. The drug achieves urinary concentrations exceeding 1000 mg/L, well above typical MICs for common uropathogens 4.
Neurotoxicity risk: Monitor for cefepime-induced neurotoxicity (CIN), particularly in patients with:
- Renal dysfunction (even mild impairment)
- Pre-existing neurological conditions
- Inadequate dose adjustments for renal function 5
When to use cefepime for UTI: Reserve cefepime for:
- Severe or complicated UTIs requiring IV therapy
- Suspected or confirmed resistant organisms (e.g., AmpC-producing Enterobacterales)
- Patients requiring carbapenem-sparing therapy
- Healthcare-associated infections 2, 6
Avoid cefepime when: First-line oral agents (nitrofurantoin, trimethoprim-sulfamethoxazole, fluoroquinolones) are appropriate for uncomplicated cystitis 7, 8.
MIC considerations: For cefoxitin-nonsusceptible ESCPM organisms, cefepime is effective when MIC ≤1 µg/mL, but carbapenems may be superior when cefepime MIC = 2 µg/mL 6.